
Vertex Pharmaceuticals (VRTX) Stock Forecast & Price Target
Vertex Pharmaceuticals (VRTX) Analyst Ratings
Bulls say
Vertex Pharmaceuticals is viewed favorably because its core cystic fibrosis franchise remains a durable, high-margin cash engine, with Q3 CF revenue of $3.27B and FY26 total revenue guidance raised to $13.15B-$13.25B on broad portfolio growth. Beyond CF, the company is increasingly diversified by the launch of Alyftrek, the expanding uptake of Journavx and Casgevy, and the pending Nov. 30 PDUFA for povetacicept, which could add another major growth leg if approved. Its pipeline breadth in kidney disease, pain, and diabetes, together with patent-protected CF leadership and multiple pivotal catalysts, supports expectations for sustained long-term revenue and earnings growth.
Bears say
Vertex Pharmaceuticals is exposed to meaningful downside as negative Pove data in IgAN could ripple across subsequent indications and undermine confidence in its renal franchise, which also faces setbacks or delays. Commercially, lower-than-expected uptake of Alyftrek and Journavx, alongside pricing pressure in cystic fibrosis and acute pain, could slow diversification away from the CF core. Competition and potential safety issues for pipeline assets such as povetacicept, suzetrigine, and inaxaplin would further erode market share and pricing power, weighing on estimates.
This aggregate rating is based on analysts' research of Vertex Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Vertex Pharmaceuticals (VRTX) Analyst Forecast & Price Prediction
Start investing in Vertex Pharmaceuticals (VRTX)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Vertex Pharmaceuticals (VRTX) Forecast
Vertex Pharmaceuticals (VRTX) Analyst Forecast & Price Prediction
Start investing in Vertex Pharmaceuticals (VRTX)
Order type
Buy in
Order amount
Est. shares
0 shares